Cann GroupASX:CAN -25.00% ROE % is 334.89% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 936 Drug Manufacturers companies, Cann Group ranks better than 97.97% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Cann Group's annualized net income for the quarter that ended in Dec. 2025 was A$52.76 Mil. Cann Group's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was A$15.75 Mil. Therefore, Cann Group's annualized ROE % for the quarter that ended in Dec. 2025 was 334.89%.
The historical rank and industry rank for Cann Group's ROE % or its related term are showing as below:
ASX:CAN'
s ROE % Range Over the Past 10 Years
Min: -400.95 Med: -29.95 Max: 116.83
Current: 116.83
During the past 9 years, Cann Group's highest ROE % was 116.83%. The lowest was -400.95%. And the median was -29.95%.
ASX:CAN's ROE % is ranked better than 97.97% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs ASX:CAN: 116.83
Cann Group (ASX:CAN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Cann Group ROE % Related Terms
Cann Group ROE % Historical Data
* Premium members only.
The historical data trend for Cann Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's ROE % distribution charts can be found below:
* The bar in red indicates where Cann Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Cann Group (ASX:CAN) has a ROE % of 334.89% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cann Group and its competitors. According to the industry distribution chart, Cann Group ranks #19 out of 936 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Cann Group's ROE % too high?
Cann Group's current ROE % is 334.89%. The Drug Manufacturers industry median ROE % is 5.87. Cann Group's value of 334.89% is 5610% above this industry median. Based on the distribution chart, Cann Group ranks #19 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #19 out of 936 companies for ROE %. This places Cann Group in the top 2% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Cann Group's value of 334.89% is 5610% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current ROE % of 334.89% is 5610% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current ROE % is 334.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current ROE % is 334.89% and 5610% above the Drug Manufacturers industry median of 5.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current ROE % is 334.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 